Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01408576 · ClinicalTrials.gov registry record · Phase 3
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3 study, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,250
- Enrollment target
NCT01408576: Completed Phase 3 study, sponsored by UCB Pharma.
NCT01408576 is a Phase 3 study that has completed, run by UCB Pharma. The registered enrollment target is 1,250 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (62% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01408576, a Phase 3 study, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,250 participants
- Enrollment target
Study Summary
The primary objective of the study is assess the safety and tolerability of long-term epratuzumab treatment in subjects with Systemic Lupus Erythematosus (SLE)
Primary Outcome
A TEAE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment.
Interventions
- DRUG Epratuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,250 participants |
| Start Date | 2011-07 |
| Est. Completion | 2016-02 |
| Phase | Phase 3 |
What the finished NCT01408576 record still lists
NCT01408576 is an interventional study that assigns participants to a tested intervention. Its 1,250 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (62% higher).
The record links to 0 conditions, and to 1 intervention - of which Epratuzumab is the first listed.
NCT01408576 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01408576 about?
NCT01408576 is a clinical study titled "Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus". The primary objective of the study is assess the safety and tolerability of long-term epratuzumab treatment in subjects with Systemic Lupus Erythematosus (SLE)
What is the current status of trial NCT01408576?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,250 participants. The study started on 2011-07. Estimated completion is 2016-02.
What interventions are being tested in trial NCT01408576?
The interventions under investigation include: Epratuzumab (DRUG).
Who is sponsoring clinical trial NCT01408576?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01408576's enrollment target sits among peer trials
1,250 207th of 2000 higher than 1,791 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02743858 · 1,250 participants
Lymphedema Surveillance Study
- NCT04670874 · 1,250 participants
Quality of Life in Cutaneous Lymphoma Patients Using the Skindex29
- NCT04807868 · 1,250 participants
AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)
- NCT05995821 · 1,250 participants
Immunobiology Blood and Tissue Collection of Upper Aerodigestive Malignancies
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia